the AAV scene [is] in some disarray and highlights the the lack...

the AAV scene [is] in some disarray and highlights the the lack of consistency between outcomes (positive and negative) across all phases, from pre-clinical, animal to humans... @Linsanity

I know that its important not to jump to conclusions because at the end of the day the FDA could simply say business as usual. However, that scenario seems unlikely given that the FDA meeting is a response to significant and growing problems in the AAV delivery mechanism space. For instance, the aforementioned article headline by Endpoints News follows an equally gripping headline from 25 January 2021 titled After 3 deaths rock the field, gene therapy researchers contemplate AAV's future.

Meanwhile PYC, following decades of development of its peptide platform culminating in the endosomal escape machinery for selecting CPPs, have arrived in the RNA therapeutics space with an alternative delivery system. The executive team may well find that the introduction 'I'm from PYC and we don't use AAV vectors' could well open many doors. Targeted, safe highly-efficient and naturally-derived delivery capable of re-dosing.

I can't help but think that the ocular program is the perfect proof of concept of a delivery mechanism for a new generation of RNA therapeutics focused upon neurodegenerative disease. Look to the area of greatest unmet need. I guess that's why the April 2021 Investor Update includes the dot point Showcase distinctive delivery of PPMO in the Central Nervous System. Welcome again to Dr Michael Rosenblatt who joined the Board in March 2021, formerly the CMO of Merck and currently a member of Moderna Therapeutics Development Committee and Vaccine Acceleration Committee.